Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia

References

• Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658–3654.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335.
   PubMed Web of Science ®Google Scholar
• Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–4380.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Socié G, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126(17):2062–2069.
   PubMed Web of Science ®Google Scholar
• Perl AE, Altman JK, Cortes JE, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18(8):1061–1075.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Oncol. 2019;20(7):984–997.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Patnaik MM, Scott BL, et al. Radius: a Phase 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML. Blood. 2018;132:662.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56(5):1180–1189.
   PubMed Web of Science ®Google Scholar
• Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201–1212.
   PubMed Web of Science ®Google Scholar
• Xuan L, Wang Y, Huang F, et al. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Cancer. 2018;124(9):1954–1963.
   PubMed Web of Science ®Google Scholar
• Burchert A, Bug G, Fritz FV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002.
   PubMed Web of Science ®Google Scholar
• Ganguly S, Cortes JE, Krämer A, et al. Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial. Transplant Cell Ther. 2021;27(2):153–162.
   PubMedGoogle Scholar
• Perl AE, Larson RA, Podoltsev NA, et al. Outcomes in patients with FLT3-mutated relapsed/ refractory acute myelogenous leukemia who underwent transplantation in the Phase 3 ADMIRAL trial of Gilteritinib versus salvage chemotherapy. Transplant Cell Ther. 2023;29(4):265.e1–265.e.10.
   Google Scholar
• Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107(2):138–150.
   PubMed Web of Science ®Google Scholar
• Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):4.
   PubMed Web of Science ®Google Scholar
• Burchet A. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. Haematologica. 2021;106(3):664–670.
   PubMed Web of Science ®Google Scholar
• Blackmon A, Aldoss I, Ball BJ. FLT3 inhibitors as maintenance therapy after allogenic stem-cell transplantation. Blood Lymphat Cancer. 2022;12:137–147.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Wolschke C, Klyuchnikov E, et al. TKI maintenance after stem-cell transplantation for FLT3-ITD positive acute myeloid leukemia: a systematic review and meta-analysis. Front Immunol. 2021;12:630429.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Allen C, Mirza1 AS, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation – a systematic review and meta-analysis. Transplantation and Cellular Therapy. 2021;27:997.e1–997.e11.
   PubMedGoogle Scholar
• Zhang Z, Hasegawa Y, Hashimoto D, et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2022;57(5):775–780.
   PubMed Web of Science ®Google Scholar
• Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735–741.
   PubMed Web of Science ®Google Scholar
• Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation. Biol Blood Marrow Transplant. 2016;22(6):982–990.
   PubMed Web of Science ®Google Scholar
• Song Y, Magenau J, Li Y, et al. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016;51(4):511–520.
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the European society for blood and marrow transplantation. Haematologica. 2020;105(6):1507–1516.
   PubMed Web of Science ®Google Scholar
• Liang EC, Chen C, Lu R, et al. Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(12):3091–3093.
   PubMed Web of Science ®Google Scholar